InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com
Company Details
- Employees
- 59
- Founded
- -
- Address
- Jena, 07745, De
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.inflarx.de/
- Keywords
- Oil and Gas.
- HQ
- Jena
Inflarx Questions
Inflarx's website is https://www.inflarx.de/
Inflarx's LinkedIn profile is https://www.linkedin.com/company/inflarx
Inflarx has
59 employees.
View email and phone details for 59
employees at Inflarx.
Inflarx's industry is
Biotechnology Research
Inflarx's top competitors are
Matrixe,
Oksoko Therapeutics,
Vocaltrans,
Archimetric Studio,
Glee Talent,
Rotaspec Equipment Services,
Water Industries Holding,
E-Agentie.ro,
Litus.fr,
The Cloud Minders.
Inflarx's categories are Biotechnology Research
Inflarx's founding year is 2007
